Female reproductive system aging: From theory to clinical practice. Part 2. Role of hormone therapy in solving the problems of transition stage and early postmenopause


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review discusses the choice of combined oral contraceptives and drugs for hormone replacement therapy in relation with clinical problems in women from late reproductive stage to early postmenopause.

全文:

受限制的访问

作者简介

Svetlana Yureneva

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
MD, senior researcher in Department of gynecological endocrinology

Lilia Ilyina

Association of Gynecological Endocrinology

Email: bseiljina@mail.ru
PhD, secretary Moscow

参考

  1. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95.
  2. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. 2009. Available at: whqlibdoc.who.int/ publications/2010/9789241563888_eng.pdf. Accessed July 13, 2012
  3. Allen R.H., Cwiak C.A., Kaunitz A.M. Contraception in women over 40 years of age. Can. Med. Assoc. J. 2013; 185(7): 565-73.
  4. Ikhena D.E., Johnson J.V. What are the options for providing contraception to perimenopausal women? Menopausal Med. 2012; 20(3): S1-6.
  5. Kaunitz A.M. Clinical practice. Hormonal contraception in women of older reproductive age. N. Engl. J. Med. 2008; 358(12): 1262-70.
  6. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 2005; 106(3): 492-501.
  7. Nappi R.E., Terreno E., Sances G., Martini E., Tonani S., Santamaria V. et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013; 88(3): 369-75.
  8. Nappi C., Bifulco G., Tommaselli G.A., Gargano V., Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012; 86(6): 606-21.
  9. Lopez L.M., Chen M., Mullins S., Curtis K.M., Helmerhorst F.M. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database Syst. Rev. 2012; 8: CD009849.
  10. Isley M.M., Kaunitz A.M. Update on hormonal contraception and bone density. Rev. Endocr. Metab. Disord. 2011; 12(2): 93-106.
  11. Committee on Practice Bulletins - Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet. Gynecol. 2013; 122(1): 176-85.
  12. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet. Gynecol. 2013; 121(4): 891-6.
  13. Fraser I.S., Parke S., Mellinger U., Machlitt A., Serrani M., Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, doubleblind, placebo-controlled trials of oestradiol valerate and dienogest. Eur. J. Contracept. Reprod. Health Care. 2011; 16(4): 258-69.
  14. Micks E.A., Jensen J.T. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv. Ther. 2013; 30(1): 1-13.
  15. Ahrendt H.J., Makalová D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44.
  16. Herman M.C., van den Brink M.J., Geomini P.M., van Meurs H.S., Huirne J.A., Eising H.P. et al. Levonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation (Novasure) in women with heavy menstrual bleeding: a multicentre randomised controlled trial. BMC Womens Health. 2013; 13(1): 32.
  17. Ozdegirmenci O., Kayikcioglu F., Akgul M.A., Kaplan M., Karcaaltincaba M., Haberal A., Akyol M. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil. Steril. 2011; 95(2): 497-502.
  18. Davis S.R., Bitzer J., Giraldi A., Palacios S., Parke S., Serrani M. et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-79. doi: 10.1111/jsm.12310.
  19. Caruso S., Agnello C., Romano M., Cianci S., Lo Presti L., Malandrino C., Cianci A. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J. Sex. Med. 2011; 8(10): 2841-50.
  20. Sitruk-Ware R., El-Etr M. Progesterone and related progestins: potential new health benefits. Climacteric. 2013; 16(Suppl.1): 69-78.
  21. Janssen I., Powell L.H., Kazlauskaite R., Dugan S.A. Testosterone and visceral fat in midlife women: the Study of Women’s Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring). 2010; 18(3): 604-10.
  22. Sitruk-Ware R. New progestagens for contraceptive use. Hum. Reprod. Update. 2006; 12(2): 169-78.
  23. De Leo V., Fruzzetti F., Musacchio M.C., Scolaro V., Di Sabatino A., Morgante G. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013; 88(3): 364-8.
  24. Bhathena R.K., Guillebaud J. Contraception for the older woman: an update. Climacteric. 2006; 9(4): 264-76.
  25. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (January 2005) contraception for women aged over 40 years. J. Fam. Plann. Reprod. Health Care. 2005; 31(1): 51-64.
  26. Reid R.L., Westhoff C., Mansour D., de Vries C., Verhaeghe J., Boschitsch E. et al. Oral contraceptives and venous thromboembolism: consensus opinion from an international workshop held in Berlin, Germany in December 2009. J. Fam. Plann. Reprod. Health Care. 2010; 36(3): 117-22.
  27. De Villiers T.J., Pines A., Panay N., Gambacciani M., Archer D.F., Baber R.J. et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.
  28. Practice bulletin no. 141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16.
  29. Kronos Longevity Research Institute. Hormone therapy has many favorable effects in newly menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study (KEEPS). Press release dated 3 October 2012. Available at: http://www.menopause.org/docs/agm/generalrelease.pdf?sfvrsn=0[accessed 2 February 2013]
  30. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902.
  31. Davison S.L., Bell R.J., Robinson P.J., Jane F., Leech J., Maruff P. et al. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial. Menopause. 2013; 20(10): 1020-6.
  32. Балан В.Е., Юренева С.В., Сметник В.П., Ильина Л.М. Кардиометаболические расстройства у женщин в постменопаузе: негативная роль андрогенов с позиций доказательной медицины. Проблемы репродукции. 2013; 3: 377-85. // Balan V.E., Yureneva S.V., Smetnik V.P., Ilina L.M. Kardiometabolicheskie rasstroystva u zhenschin v postmenopauze: negativnaya rol androgenov s pozitsiy dokazatelnoy meditsinyi. Problemyi reproduktsii. 2013; 3: 377-85.
  33. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br. Med. J. 2012; 345: e6409.
  34. Heinemann K., Assmann A., Dinger J. The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiol. Drug Safety. 2012; 21(Suppl.3): 365.
  35. Salpeter S.R., Walsh J.M., Greyber E., Salpeter E.E. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern. Med. 2006; 21(4): 363-6.
  36. Salpeter S.R., Walsh J.M., Greyber E., Ormiston T.M., Salpeter E.E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J. Gen. Intern. Med. 2004; 19: 791-804.
  37. Preston R.A., White W.B., Pitt B., Bakris G., Norris P.M., Hanes V Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am. J. Hypertens. 2005; 18(6): 797-804.
  38. White W.B., Pitt B., Preston R.A., Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005; 112: 1979-84.
  39. Duprez D., Toleuova A. Prehypertension and the cardiometabolic syndrome. Pathological and clinical consequences. Expert Rev. Cardiovasc. Ther. 2013; 11(12): 1725-33.
  40. Palacios S., Foidart J.-M., Genazzani A.R. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006; 55(4): 297-307.
  41. Foidart J.-M., Faustmann Th. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol. Endocrinol. 2007; 23(12): 692-9.
  42. Villa P., Suriano R., Ricciardi L., Tagliaferri V., De Cicco S., De Franciscis P. et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil. Steril. 2011; 95(1): 158-63.
  43. Archer D.F., Thorneycroft I.H., Foegh M., Hanes V., Giant M.D., Bitterman P., Kempson R.L. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005; 12(6): 716-27.
  44. Tanko L.B., Christiansen C. Effects of 17β-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J. Intern. Med. 2005; 258(6): 544-53.
  45. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospi-renone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25.
  46. De Franciscis P., Mainini G., Labriola D., Leo S., Santangelo F., Luisi A. et al. Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome. Clin. Exp. Obstet. Gynecol. 2013; 40(2): 233-5.
  47. Rizzo M.R., Leo S., De Franciscis P., Colacurci N., Paolisso G. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014; 36(1): 265-74.
  48. Archer D.F., Schmelter T., Schaefers M., Gerlinger C., Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014; 21(3): 227-35. doi: 10.1097/ GME.0b013e31829c1431.
  49. Sturdee D.W., Pines A.; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14(3): 302-20.
  50. ACOG Committee Opinion on Gynecologic Practice № 565: hormone therapy and heart disease. Obstet. Gynecol. 2013; 121(6): 1407-10.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##